Lexicon Announces Appointment of Lonnel Coats as President and Chief Executive Officer

Lexicon Announces Appointment of Lonnel Coats as President and Chief Executive

PR Newswire

THE WOODLANDS, Texas, July 7, 2014

THE WOODLANDS, Texas, July 7, 2014 /PRNewswire/ --Lexicon Pharmaceuticals,
Inc. (Nasdaq: LXRX) announced today that Lonnel Coats has been appointed
president and chief executive officer effective July 7, 2014. Mr. Coats most
recently served as president and chief executive officer of Eisai Inc., the
United States subsidiary of Eisai Co., Ltd.

Mr. Coats joins Lexicon after 18 years of senior management experience with
Eisai. As president and chief executive officer at Eisai, he oversaw the
commercialization of Eisai products in the therapeutic areas of oncology,
neurology, GI, epilepsy and metabolic. Mr. Coats also oversaw the expansion
of Eisai's business across the Americas, inclusive of gaining market approval
in Canada for Halaven, Banzel and Gliadel. Previously, as president and chief
operating officer, Mr. Coats led the diversification of Eisai's business
through over $5 billion in strategic acquisitions, licensing and partnerships,
which included the acquisition of MGI Pharma in 2008 and the licensing of
Belviq in 2011.

"In our search for the next leader of Lexicon, we sought a seasoned and
dynamic executive with an exceptional understanding of bringing drugs to the
market," said Raymond Debbane, Lexicon's chairman of the board. "Lonnel brings
the ideal blend of operational intelligence, business development acumen and
proven leadership, along with a breadth of expertise in sales and marketing to
guide Lexicon as we prepare for commercialization."

"Upon my retirement from Eisai, I had the privilege to be presented with many
new opportunities to continue contributing to our great industry," said Lonnel
Coats. "By far, Lexicon is the most exciting and promising opportunity I
reviewed. Lexicon is on the cusp of becoming a major contributor to improving
the lives of patients living with type 1 and 2 diabetes, with carcinoid
syndrome and with many other conditions. We have much work to do before we
achieve all of our goals, but I am enthusiastic and energized at our
prospects. I am honored to have the trust of the board of directors and
management to lead Lexicon through the next phase of its evolution."

Mr. Coats originally joined Eisai as a regional sales director in 1996 when
the company was first establishing its sales force in the United States in
preparation for the launch of Aricept. In 2001, he became vice president of
human resources, and in 2003, he was appointed vice president of U.S. sales
and marketing, before serving as president and chief operating officer from
2004 to 2010 and as president and chief executive officer since 2010. Mr.
Coats holds a B.S. in public administration from Oakland University in

About Lexicon

Lexicon is a biopharmaceutical company focused on developing breakthrough
treatments for human disease. Lexicon currently has drug programs in clinical
development for diabetes, carcinoid syndrome, and other indications, all of
which were discovered by Lexicon's research team. Lexicon has used its
proprietary gene knockout technology to identify more than 100 promising drug
targets. For additional information about Lexicon and its programs, please
visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements
relating to Lexicon's growth and future operating results, discovery and
development of products, strategic alliances and intellectual property, as
well as other matters that are not historical facts or information. All
forward-looking statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to meet its capital
requirements, successfully conduct preclinical and clinical development of its
potential drug candidates, advance additional candidates into preclinical and
clinical development, obtain necessary regulatory approvals, achieve its
operational objectives, obtain patent protection for its discoveries and
establish strategic alliances, as well as additional factors relating to
manufacturing, intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual results to be
materially different from any future results expressed or implied by such
forward-looking statements. Information identifying such important factors is
contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the
year ended December 31, 2013, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.

Website: http://www.lexpharma.com
Contact: Chas Schultz, Senior Director, Finance and Communications, Lexicon,
281/863-3421, cschultz@lexpharma.com
Press spacebar to pause and continue. Press esc to stop.